Article Text


Autosomal dominant burning feet syndrome
  1. Florian Stögbauera,
  2. Peter Younga,
  3. Gregor Kuhlenbäumera,d,
  4. Reinhard Kiefera,
  5. Vincent Timmermand,
  6. E Bernd Ringelsteina,
  7. Jian-Feng Wangb,
  8. J Michael Schröderb,
  9. Christine Van Broeckhovend,
  10. Joachim Weisc
  1. aDepartment of Neurology, University of Münster, Germany, bDepartment of Neuropathology, University of Aachen, Germany, cInstitute of Pathology, University of Bern, Switzerland, dNeurogenetics Laboratory, Flanders Interuniversity Institute for Biotechnology (VIB), Born Bunge Foundation (BBS), Department of Biochemistry, University of Antwerp (UIA), Belgium
  1. Dr Florian Stögbauer, Department of Neurology, University of Münster, Albert Schweitzer Strasse 33, D-48129 Münster, Germany. Telephone 0049 251 8348178; fax 0049 251 8348181; email stogbau{at}


Familial burning feet syndrome inherited as an autosomal dominant trait has been described in only one family. Due to an associated sensory neuropathy the autosomal dominant burning feet syndrome was suggested to represent a variant form of hereditary sensory and autonomic neuropathy type I (HSAN I). Clinical, histopathological, and molecular genetic studies were performed in a large German kindred with autosomal dominant burning feet syndrome. The autosomal dominant burning feet syndrome was associated with a neuropathy predominantly affecting small unmyelinated nerve fibres. Linkage to the HSAN I locus on chromosome 9q22 and to the Charcot-Marie-Tooth disease type 2B (CMT 2B) locus on chromosome 3q13-q22 was excluded. The autosomal dominant burning feet syndrome is neither allelic to HSAN I nor to CMT 2B and thus represents a distinct genetic entity.

  • burning feet syndrome: hereditary sensory neuropathy

Statistics from

Burning feet syndrome is characterised by burning, tingling, numbness, and a dull ache in the feet and legs. Symptoms are worsened by heat and ameliorated by cooling. Several causes have been described, including vitamin deficiency and poor nutritional status.1-3Burning feet were occasionally found to be associated with tarsal tunnel syndrome and gastric surgery.4 5

To date, only one family has been reported in which burning feet were the only clinical manifestation of a dominantly inherited sensory neuropathy.6 In this family clinical and neurophysiological studies of affected members showed only mild abnormalities but in sural nerve biopsies increased frequencies of demyelinating and remyelinating teased fibres were found. The authors concluded that the inherited form of burning feet syndrome might represent a different type of hereditary sensory and autonomic neuropathy type I (HSAN I) or a sensory neuropathy distinct from HSAN I.

Hereditary sensory and autonomic neuropathies represent a heterogenous group of disorders of sensory and autonomic nerves. Six subtypes of HSAN were classified7; HSAN I typically presents as a distal lower limb sensory and autonomic neuropathy with skin injuries sometimes leading to acral mutilation. Clinical features may also include lancinating pain, muscle weakness, sensory ataxia, spasticity, and neurogenic arthropathy. Whether this clinical heterogeneity represents defects in different genes or different alleles of the same gene is not known.

Recently, the chromosomal locus for HSAN I was mapped to chromosome 9q22.1-q22.3.8 The chromosomal locus of another autosomal dominant neuropathy with prominent sensory abnormalities, Charcot-Marie-Tooth disease type 2B (CMT 2B), was mapped to chromosome 3q13-q22.9-11 As there are overlaps in the phenotype of HSAN I and CMT 2B it has been proposed that CMT 2B should rather be classified as HSAN I, implying multiple gene loci for this syndrome.12

In the present report, we describe another family in which the burning feet syndrome was inherited as an autosomal dominant trait. Clinical, neurophysiological, histopathological, and molecular genetic studies were performed.

Patients and methods

A German kindred was diagnosed with autosomal dominant burning feet syndrome. Sixty eight family members including 10 affected members were available for this study (fig 1). Twenty seven members including all patients underwent neurological examination and 20 members were used in the linkage studies.

Figure 1

Pedigree of the German family with autosomal dominant burning feet syndrome. Slashed=deceased; squares=males; circles=females; filled=affected members; empty=non-affected members. The propositus is marked with an arrow. Those that were used in linkage studies are marked by an asterix.

Nerve conduction studies and needle EMG were performed according to standard techniques. Three affected members of the family including the propositus were investigated (III:31, 49 years; III:33, 55 years; IV:30, 27 years).

A sural nerve biopsy of the index patient (III:31) was examined by light and electron microscopy as described elsewhere.13Semithin cross sections of 455 randomly selected myelinated nerve fibres from several fascicles were stained with toluidine blue and evaluated morphometrically using a digital image analysis system (Kontron KS 300, Munich, Germany).

Short tandem repeat (STR) analysis was performed with the chromosome 9q22.1-q22.3 markers D9S257, D9S196, D9S197, D9S280, D9S910, and the chromosome 3q13-q22 markers D3S1769, D3S1551, D3S1290, and D3S1744 as described.14-16 Two point linkage analysis was performed with the FASTLINK computer package.17 We assumed that the disease is transmitted as a fully penetrant autosomal dominant trait with a gene frequency of 1/10.000. Allele frequencies of the dinucleotide repeat markers were obtained from the Genome Data Base ( The allele frequencies of the markers D9S910, D3S1769, and D3S1744 are not known. Therefore we used equal allele frequencies for these markers. Haplotypes were constructed according to the genetic map of Dib et al,15 and the Cooperative Human Linkage Center (


The burning feet syndrome was inherited as an autosomal dominant trait (fig 1). The onset of symptoms ranged between 12 and 40 years (median 26.8). The affected family members showed a homogeneous phenotype. Pain was the main symptom and present in all affected members. They complained of symmetric burning and dull aching pain in the feet, predominantly affecting the soles and toes with progressive involvement of the ankles and lower legs. Symptoms did not occur in the hands and forearms, worsened when the feet were warm, and were ameliorated by cooling. There were no complaints of weakness or clinical signs of autonomic disturbances.

On neurological examination, no muscular atrophy or muscle weakness was found in the affected family members, and tendon reflexes were normal. None of the patients had high arched feet, pes cavus, or other skeletal abnormalities. Touch, pain, temperature,and vibration sensation as well as position sense were normal.

In the index patient (III:31), nerve conduction studies of the right tibial nerve showed a slightly reduced amplitude of the compound muscle action potential of the extensor digitorum brevis muscle and axon reflexes in F wave recordings. The distal motor latency, nerve conduction velocity, and F wave latency were normal. Motor nerve conduction and F wave studies of the right median and ulnar nerve were normal. Sensory nerve conduction studies of the right median, ulnar, and sural nerve were normal except for a slight reduction in amplitude of the ulnar sensory nerve action potential, with a normal amplitude on the opposite side. On EMG of the right tibialis anterior muscle, no pathological spontaneous activity was detected. However, recruitment of motor units was reduced and the mean amplitude of motor unit action potentials was increased, compatible with a mild chronic neurogenic process. Nerve conduction studies and EMG of III:33 were normal except for A waves present on F wave recordings from the right tibial nerve. Electrophysiological testing of IV:30 gave normal results.

On sural nerve biopsy (III:31) there was moderate reduction of myelinated nerve fibres, especially of the smaller ones, which was partially compensated by regenerated fibres (fig 2 A). Repeatedly, myelin debris, small clusters of regenerated myelinated nerve fibres, and disproportionately thin myelin sheaths around large axons were found. Most strikingly, however, a marked reduction of unmyelinated nerve fibres was found by electron microscopy. Numerous collagen pockets indicating loss of unmyelinated nerve fibres and Schwann cell processes without any association with axons were seen (fig 2 B). The morphometrical analysis of myelin sheaths and axonal areas disclosed that the total number of myelinated nerve fibres per endoneural area was just below the lower normal range (5912/mm2; normal range 6000–9000/mm2) due to an increase of small regenerated nerve fibres. Accordingly the myelin area per endoneural area was only moderately reduced (17.9%; normal range 20%-30%). At the electron microscopic level, there were 167 empty Schwann cell processes per 231 unmyelinated axons and 68 myelinated nerve fibres as counted on 32 electron migrographs (total area evaluated: 0.0076 mm2), indicating loss of unmyelinated nerve fibres.

Figure 2

(A) Occasional degenerating myelinated fibres (arrow), myelin breakdown products, and small clusters of regenerating nerve fibres (arrowhead) were found in transverse semithin sections of the sural nerve. Epon, paraphenylendiamine (originally×400). (B) On electron microscopy, bundles of collagen fibres are seen surrounded by Schwann cell processes (“collagen pockets”; arrows), indicating preceeding degeneration of unmyelinated axons. Isolated Schwann cells and stacks of Schwann cell processes (bands of Buenger) at the site of degenerated myelinated fibres are also apparent (large arrowheads). A preserved unmyelinated axon is indicated by a small arrowhead (originally×23000).

Genetic linkage was performed with STR markers that cover the complete HSAN I candidate region on chromosome 9q22.1-q22.3. Haplotype analysis showed multiple recombinants and significant negative lod scores were obtained with all markers. Haplotype analysis of the CMT 2B locus on chromosome 3q13-q22 also showed multiple recombinants. Significant negative lod scores over the whole region were obtained. Thus, the autosomal dominant burning feet syndrome in our family is not allelic to HSAN I and CMT 2B.


The burning feet syndrome is clinically heterogeneous and associated with vitamin deficiency and poor nutritional status.1 2 Only one family was reported in which the burning feet syndrome was inherited as an autosomal dominant trait.7

We describe a large German family with autosomal dominant burning feet syndrome. Similar to the kinship reported by Dycket al,6 the onset of symptoms was in the second to fourth decade of life. Careful and complete neurological examination failed to detect objective clinical evidence of the underlying neuropathy. However, quantitative psychophysical studies to investigate pain and temperature thresholds could not be performed. Others have found that these are abnormal in a subpopulation of patients with burning feet syndrome possibly indicating involvement of small unmyelinated fibres.18 On neurophysiological examination there were minor abnormalities on motor nerve conduction studies and EMG in two patients. These data point towards a mild axonal neuropathic process involving motor nerves. However, the changes are very mild and not necessarily related to burning feet syndrome as such minor abnormalities are often found in older patients due to subclinical motor root involvement after degenerative spinal disease. Histopathologically, the myelinated nerve fibre density was moderately reduced. Most notably, however, there was a marked reduction in the density of unmyelinated nerve fibres. This reduction might reflect predominant involvement of this fibre population. Similar findings have been described in HSAN and are in line with the above mentioned abnormalities of small fibre function in burning feet syndrome.7 18

Clinical as well as histopathological data on the families described suggest that the autosomal dominant burning feet syndrome is the main manifestation of a primarily sensory neuropathy with predominant involvement of unmyelinated fibres. With regard to the age of onset of the disease and the preferential involvement of the lower limbs it was proposed that the burning feet syndrome may represent one of the variant forms of HSAN type I in which sensory disturbances (lancinating pain or burning feet) are the only signs of a sensory neuropathy.6

Recently, the chromosomal locus for HSAN I has been mapped to chromosome 9q22.1-q22.3.8 Molecular genetic analysis excludes the HSAN I locus in our family. CMT 2B has been mapped to chromosome 3q13-q22.10 11 Along with minor motor nerve involvement, sensory symptoms are prominent in this neuropathy. Patients often have distal sensory loss and non-healing ulcerations sometimes leading to amputations. Because of this overlap of symptoms it has been suggested that the disease condition is misclassified and represents more likely a subtype of HSAN I.12 The sensory symptoms in the family we describe are milder but it is not uncommon that different mutations in the same gene may lead to phenotypes of different severities. For example, different mutations in themyelin protein zero gene can lead to a wide range of phenotypes.19 Nevertheless, molecular genetic analysis excludes the CMT type 2B locus as well.

In conclusion, our results confirm the presence of a predominantly sensory neuropathy in autosomal dominant burning feet syndrome. The results of the molecular genetic studies exclude linkage to both known loci of inherited sensory neuropathies (HSAN I and CMT 2B). Thus, the autosomal dominant burning feet syndrome most likely represents a separate disease entity.


F Stögbour and P Young contributed equally to the work presented in this article.

We are grateful to the patients and their relatives for their kind cooperation in our research project and to Mrs A Knischewski, Mrs E Beck, Mrs E De Vriendt, and Mrs H Mader for technical assistance. This work was supported in part by a grant from the Fund for Scientific Research (FWO), Flanders-Belgium. VT is a research assistant of the FWO, Belgium. GK is supported by the Deutsche Forschungsgemeinschaft (KU 1194/1–1). CVB is the coordinator of the European CMT Consortium sponsored by an EU BIOMED2 grant (CT 96–1614).


View Abstract

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.